Marked reduction in apoptosis is a hallmark of early colon tumour growth and the vast majority of these tumours exhibit a loss of expression of the glycoprotein carcinoembryonic-antigen-related cell adhesion molecule 1 (CEACAM1). We recently reported that the CEACAM1 functions as a mediator of apoptosis implicating this cell surface protein in early tumour development. However, the mechanistic involvement of CEACAM1 in cell death pathways is unclear. Here, we show that apoptosis triggers cleavage of the long form of CEACAM1 (CEACAM1-4L) at intracellular and extracellular sites in Jurkat cells and HEK293 cells. Signalling through CEACAM1 leads to caspase activation including caspase-1 and -3 and also involves non-caspase proteases. Moreover, we provide evidence that the naturally occurring CEACAM family member CEA is an inducer of CEACAM1-mediated apoptosis in HT29 colon cancer cells, an effect that depends on the abundance of CEACAM1 on the cell surface. Together, our results demonstrate that the CEACAM1-dependent cell death pathway involves dual cleavage of CEACAM1 and caspase activation and can be activated by CEA.
Introduction
Normal tissue architecture requires complex and coordinate gene expression programs which maintain an intricate balance between cell proliferation, differentiation and apoptosis. In high-turnover tissues such as the colonic crypt mucosa, epithelial cells continuously migrate towards the intestinal crypt lumen. After several differentiation stages, they reach the crypt surface, undergo apoptosis and are ultimately shed into the gut lumen. It is likely that defects in the apoptosis machinery of these cells play a critical role in tumour initiation. For example, it has been shown that reduced apoptosis leads to the disturbance of tissue homoeostasis in the so-called hyperplastic aberrant crypt foci, the earliest detectable tumour lesion in the colon (Roncucci et al., 1991) . However, the molecular control of programmed cell death in differentiated colon crypt cells is still poorly understood.
The carcinoembryonic-antigen-related cell adhesion molecule (CEACAM) family constitutes a group of highly homologous proteins that are expressed in a variety of human tissues (Hammarstrom, 1999) . Its members can interact by homophilic and heterophilic adhesion. Various CEACAMs are expressed in the differentiating colon mucosa which localize to the apical luminal surface of the colonic crypt cells where these are a major constituent of the glycocalix.
CEACAM1 is a membrane-bound protein found in microvilli of the apical colon cell surface (Baranov et al., 1994; Frangsmyr et al., 1999) . It is composed of four extracellular domains and a long (CEACAM1-4L) or short (CEACAM1-4S) cytoplasmic domain which are encoded by alternative splicing (Hinoda et al., 1988; Barnett et al., 1989) . The cytoplasmic domains of CEACAM1 are phosphorylated at their serine residues (Edlund et al., 1998; Fournes et al., 2001 ) and bind to calmodulin (Edlund et al., 1996) . The CEACAM1-4L domain contains two tyrosine residues that recruit and activate pp60 c-src (Brummer et al., 1995) or the phosphatases SHP1 and -2 (Huber et al., 1999) upon phosphorylation. Signal transduction through the cytoplasmic domains appears to be important for the tumour suppressor function of CEACAM1 that has been initially suggested by clinical studies (Neumaier et al., 1993b; Nollau et al., 1997b) and subsequently by in vitro experiments and animal studies (Kunath et al., 1995; Obrink, 1997; Singer et al., 2000) .
Importantly, the vast majority of early and advanced types of colon tumour lesions are characterized by a loss of CECAM1 expression (Neumaier et al., 1993a; Nollau et al., 1997a) , strongly suggesting its implication in the pathogenesis of colon cancer. CEACAM1 plays an important role in the morphogenesis in human breast tissues where it is associated with apoptosis in differentiating epithelial cells (Huang et al., 1999; Kirshner et al., 2003) . We recently demonstrated that crosslinking of CEACAM1 on the cell surface of tumour cells mediates apoptosis (Nittka et al., 2004) . Moreover, the loss of CEACAM1 is associated with reduced apoptosis in early colon tumour lesions in vivo, whereas normal apoptosis rates are found in CEACAM1-expressing tumours.
In this study, we investigated the molecular events that are associated with CEACAM1-mediated apoptosis. We now demonstrate that induction of apoptosis leads to dual cleavage of CEACAM1, involves activation of specific caspases and depends on carcinoembryonic antigen (CEA), the prototypic member of the CEACAM family.
Results

Apoptosis induces dual cleavage of the intracellular and extracellular domains of CEACAM1-4L
We previously demonstrated that antibodies directed against CEACAM1 induce programmed cell death in Jurkat cells (Nittka et al., 2004) , suggesting that CEACAM1 is capable of activating the cellular apoptosis machinery. To gain more insight into the involvement of CEACAM1 in apoptosis pathways, we tested whether CEACAM1 is modified during apoptosis. For this, apoptosis was induced in Jurkat cells which overexpress the CEACAM1-4L splice variant for 24 h using five independent stimuli including an anti-Fas monoclonal antibody (mAb), camptothecin (0.5 mM), etoposide (50 mM), cycloheximide (0.5 mM) and actinomycin D (1 mM), respectively. After deglycosylation with PNGaseF, western analysis of total cell lysates using the CEACAM-specific mAb T84.1 revealed a 58 kDa band in addition to the 70 kDa canonical protein which was present after incubation with all apoptosis stimuli ( Figure 1a) . Parental Jurkat cells (controls) did not express CEACAM1. A 58 kDa band has been reported by others during the course of this study. It is likely generated by cleavage of CEACAM1-4L at the intracellular domain and its size corresponds to that of CEACAM1-4S (Houde et al., 2003) .
In addition, we detected an additional peptide of B50 kDa size in the lysates of apoptotic Jurkat cells. The identity of the 50 kDa polypeptide was confirmed using a second CEACAM1-specific (29H2) monoclonal antibody and a goat a-CEACAM1 serum (Figure 1b) . Importantly, the 50 kDa fragment was also found when apoptosis was induced by CEACAM1-4L crosslinking (Figure 1b) . To map the position of this cleavage site generating the 50 kDa CEACAM1 fragment, we expressed CEACAM1-4L as a fusion protein with an extracellular (N-terminal) FLAG tag in HEK293 cells (FLAG/CEACAM1-4L). When apoptosis was induced in these cells, we detected a B14 kDa peptide fragment in the supernatant which was recognized by both the CEACAM1-specific T84.1 antibody (not shown) and the anti-FLAG antibody M2 (Figure 1c ). Because both antibodies are directed against the CEACAM1 N terminus, this maps the cleavage site to the extracellular domain of CEACAM1. Together these results indicate that apoptosis induces dual cleavage of CEACAM1 at intracellular and extracellular sites.
To further visualize the intracellular cleavage site of CEACAM1, we generated a monoclonal antibody (mAb 7-2.3) against amino acids (aa) 483-502 of the long cytoplasmic domain of CEACAM1-4L. Control experiments in HT29 cells and CEACAM1-4L overexpressing HEK293 cells demonstrated that mAb 7-2.3 specifically detects B120 kDa glycosylated forms and the 70 kDa deglycosylated form of CEACAM1-4L (Figure 2) . Moreover, immunocytochemical analysis in CEA-CAM1-4L, CEA and CEACAM6 overexpressing cells, respectively, revealed that mAb 7-2.3 specifically recognizes CEACAM1-4L, but not CEACAM1-4S or other CEACAM family members ( Figure 2 ).
We next looked for evidence of apoptosis-induced intracellular cleavage of CEACAM1-4L on the subcellular level. Immunocytochemistry in CEACAM1-4L overexpressing apoptotic HEK293 cells using the cytoplasmic domain-specific mAb 7-2.3 indeed revealed clustering of the CEACAM1 C-terminal fragment in the cytoplasm as compared to the control cells ( Figure 3 ). This finding is consistent with the view that proteolytic cleavage of CEACAM1-4L at the cytoplasmic domain leads to redistribution of the intracellular fragment in the cytoplasm.
We then performed a detailed analysis of apoptosismediated extracellular processing of CEACAM1-4L and CEACAM1-4S on the cell surface. Apoptosis induced by camptothecin led to a significant reduction of CEACAM1-4S (À22%) and CEACAM1-4L (À35%) cell surface expression, respectively, in Jurkat cells as Figure 1 Apoptosis induces intracellular and extracellular cleavages of carcinoembryonic-antigen-related cell adhesion molecule 1 (CEACAM1). Note the consistent presence of a 58 and a 50 kDa (arrow) cleavage product in normal (P), CEACAM1-4L (CL) and CEACAM1-4S (CS) overexpressing Jurkat cells after induction of apoptosis using five different stimuli (a, b). Western analysis was performed on deglycosylated whole cell lysates using the CEA-CAM1-specific monoclonal antibodies T84.1 and 29H2 and a goat a-CEACAM1-specific serum, respectively. (c) Apoptosis-induced cleavage of N-FLAG-tagged CEACAM1-4L in HEK293 cells results in the shedding of a B14 kDa peptide fragment (arrow) as detected by a FLAG-specific antibody but not in healthy control cells. Camp, camptothecin; CHX, cycloheximide; actD, actinomycin D.
Activation and processing of CEACAM1 during apoptosis S Nittka et al assessed by flow cytometry using the T84.1 antibody ( Figure 4a ). Similarly, induction of apoptosis by cycloheximide or actinomycin D resulted in a 24% reduction of CEACAM1 staining on the cell surface of HT29 colon cells indicating that programmed cell death leads to extracellular shedding of a significant portion of CEACAM1 (Figure 4b ).
Tetrapeptide inhibitors suppress caspase activation in CEACAM1-mediated apoptosis To identify the caspases that are involved in CEA-CAM1-induced apoptosis, we tested the effect of tetrapeptide substrates with various defined caspase specificities. These included Ac-VEID-pNA (caspase-6), Ac-IETD-pNA (caspase-8), Ac-LEVD-pNA (caspase-4), Ac-WEHD-pNA (caspase-1, -4, -5) and Ac-DEVDpNA (caspase-3, -6, -7, -8, -10). Using this approach, significantly elevated cleavage rates for Ac-WEHDpNA and Ac-DEVD-pNA were found in the cell lysates of CEACAM1-4L Jurkat cells 16 h after the induction of apoptosis. This strongly suggests the involvement of caspase-1, -3 and -7, respectively, in CEACAM1-mediated apoptosis (Figure 5a ). Consistent with this, the pan-caspase inhibitor Z-VAD.fmk markedly suppressed CEACAM1-dependent apoptosis in Activation and processing of CEACAM1 during apoptosis S Nittka et al CEACAM1-4L Jurkat cells (Figure 5b ). This effect was not observed when the peptide Z-FA.fmk, which does not affect caspase activity, was used as control.
Additional proteases are activated by induction of CEACAM1-dependent apoptosis
The observation that the blockade of caspase-1, -3 and -7, respectively, strongly inhibited, but did not completely abolish CEACAM1-mediated apoptosis in Jurkat cells suggested the implication of additional proteases in this pathway. In fact, incubation of whole cell lysates with various protease inhibitors demonstrated significant inhibition of cathepsin B (39%), aspartate proteases (17%) and metalloproteinases (MMPs, 32%) by their specific inhibitors (leupeptin, pepstatin and phosphoramidon, respectively) which indicates that these were activated by CEACAM1 crosslinking (Figure 5c ). These results demonstrate the implication of additional non-caspase proteases in CEACAM1-4L-mediated apoptosis.
Carcinoembryonic antigen induces CEACAM1-dependent initiation of apoptosis in differentiated HT29 cells Given these results largely based on crosslinking experiments, we addressed the question about the nature of a physiological stimulus inducing programmed cell death through the CEACAM1-dependent pathway. Two HT29 cell sublines extensively differing in their CEACAM1 expression levels (designated HT29 CEA-CAM1 high and low expressor) were used ( Figure 6a ) in cell death detection enzyme-linked immunosorbent assay (ELISA) experiments. Specifically, when incubated with purified CEA (4-100 ng ml À1 ), we observed a dose-dependent induction of apoptosis in the CEA-CAM1 high expressor cells, while no effect was observed in HT29 cells with low CEACAM1 production ( Figure 6b ). These results demonstrate that CEA, a wellknown ligand of CEACAM1, can act as a physiological inducer of the CEACAM1-dependent apoptosis pathway. Furthermore, the dose dependency implies that CEA-mediated apoptosis is regulated by the abundance of CEACAM1 on the cell surface.
Discussion
Our results demonstrate that induction of apoptosis through various stimuli, but also CEACAM1 per se, induces intracellular and extracellular cleavages of CEACAM1. One of the two cleavage sites is a caspase-3 site within the long cytoplasmic domain. This site has been characterized previously (Houde et al., 2003) and it was shown that purified effector caspase-3 can cleave the long CEACAM1 cytoplasmic domain at the DQRD motif near the C terminus of CEACAM1-4S (Supplementary Figure 1) . Our results demonstrating that induction of apoptosis in CEACAM1-4L transfectants generates a peptide with a molecular mass of B58 kDa which has a similar size as CEACAM1-4S are consistent with this finding. It is thus conceivable that apoptosis induction may trigger cleavage of CEA-CAM1-4L within the cytoplasmic domain by caspase-3 activity also in vivo. 
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Beside intracellular cleavage, we found that apoptotic stimuli also induce cleavage of CEACAM1 at a second site. Antibody mapping in CEACAM1-4L Jurkat cells and HT29 cells revealed that cleavage occurs at the extracellular domain and, after deglycosylation, shows the generation of an 8 kDa fragment. The cleavage product we detected in apoptotic HEK293 cells overexpressing a FLAG/CEACAM1-4L fusion protein, however, was B14 kDa in size. This discrepancy is most likely due to glycosylation. In fact, the extracellular domain of CEACAM1 exhibits three N-glycosylation sites at aa 70, 77 and 80, respectively (Paxton et al., 1987; Hefta et al., 1988; Charbonneau and Stanners, 1999) . The predicted molecular weight of the first CEACAM1 70 aa is 7.9 kDa, whereas that of aa 1-77 is 8.5 kDa. Assuming tetraantennary sugar chains in the N-domain, which have a calculated molecular mass of 6 kDa, the observed 14 kDa fragment allocates the extracellular cleavage site to a segment between aa 70 and 77. This putative topology is shown in Supplementary Figure 1 . The function of the extracellular cleavage of CEACAM1-4L is currently unknown. Because homophilic binding of CEACAM1 isoforms critically depends on the presence of the N-terminal domain (Watt et al., 2001) , removal of the N-domain may result in a dissociation of CEACAM1 molecules. This may provide a mechanism, which abrogates continuous signalling through the CEACAM1 pathway.
While receptor-mediated apoptosis usually involves the activation of caspase-8 and -3, we observed an activation of caspase-1 and -3 and also -7. Activation of caspase-1 has mostly been implicated in inflammatory responses; however, its implication in apoptotic processes has also been documented (Hilbi et al., 1998; Liu and Abrams, 2003) . In Fas-induced apoptosis, the activation of the primarily inflammation associated caspase-1 and -4 provides an amplification loop to enhance apoptosis, a function that has often been implicated in pathways involving caspase-1 activation. CEACAM1-4L-mediated apoptosis did not lead to activation of caspase-8, which is consistent with the fact that CEACAM1 lacks a death domain that is required for the formation of the caspase-8-associated deathinducing signalling complex. It appears that no direct pathway for caspase-1 activation through CEACAM1 signalling exists. This raises the question as to how caspase-1 and -3 are activated. Because we found no evidence for activation of initiator caspases, it is likely that procaspases are processed by activating proteases. Our experiments using specific protease inhibitors suggest the involvement of non-caspase proteases in CEACAM1-4L-induced apoptosis including aspartate proteases, metalloproteinases and cathepsin B. In fact, activation of caspase-1 by cathepsin B and inhibition of the corresponding apoptosis pathway by the addition of Z-VAD.fmk have been well documented (Vancompernolle et al., 1998) . It is thus likely that procaspase activation may be initiated by these proteases.
Our study provides evidence, for the first time, that CEA functions as an inducer of CEACAM1-mediated apoptosis in HT29 colon cancer cells. Importantly, we found that this effect depends on the abundance of CEACAM1 at the cell membrane, since it was observed only in CEACAM1 high expressor HT29 cells but not in Activation and processing of CEACAM1 during apoptosis S Nittka et al HT29 cells that express only low amounts of CEA-CAM1. This finding indicates that CEACAM1 is the rate-limiting factor when apoptosis is induced which is consistent with our previous observation that loss of CEACAM1 is associated with reduced apoptosis in the early tumour lesions (Nittka et al., 2004) . Because CEA and CEACAM1 are positioned in close spatial proximity at the plasma membrane of colonocytes (Baranov et al., 1994; Frangsmyr et al., 1995) , our results provide a mechanistic basis through which CEA may be directly involved in the control of apoptosis in colon epithelial cells in vivo. In such a setting, the apoptogenic interaction between CEA and CEACAM1 may play a critical role in colon tumourigenesis. It will be challenging to test this fascinating hypothesis in the future.
A role of CEACAM1 has also been demonstrated in the morphogenesis and lumen formation of the human breast and transfection of MCF7 breast cancer cells with CEACAM1-4S induces massive apoptosis (Huang et al., 1999; Kirshner et al., 2003) . Moreover, transient expression of CEACAM1-4L in MCF7 leads to rapid cell decay (unpublished data). In contrast, the immortalized cell line MCF10 is tolerant to CEACAM1-4L expression (Huang et al., 1999) . In light of our findings, the dramatic apoptotic response of MCF7 cells to CEACAM1 overexpression can be explained by the fact that these cells express large amounts of CEA, whereas MCF10 fails to produce significant quantities of CEA, suggesting that the availability of both CEA ligand and CEACAM1 may critically determine the extent of the apoptotic response in tumour cells.
In conclusion, we demonstrate intracellular and extracellular processing of CEACAM1 in response to apoptotic stimuli which results in two truncated CEACAM1 variants. We show that initiation of the CEACAM1-dependent apoptosis involves caspases but also non-caspase proteases. Moreover, we identified CEA as a naturally occurring activator of the CEA-CAM1-dependent apoptosis pathway.
Materials and methods
Reagents, antibodies and cell culture Caspase substrates, inhibitors and human CEA were purchased from Calbiochem (San Diego, CA, USA), BioCat (Heidelberg, Germany) and Sigma (Taufkirchen, Germany), respectively. CEACAM1 antibodies 8G5 (Genovac, Freiburg, Germany) and T84.1 (generous gift from Dr J Shively, Duarte, CA, USA) were used in combination with PE-conjugated goat antibodies (DAKO Cytomation, Glostrup, Germany). The anti-human Fas antibody CH11 was from Beckman Coulter (Krefeld, Germany). A monoclonal anti-CEACAM1 antibody (mAb 7-2.3) was generated against a KLH-coupled fragment of the CEACAM1-4L cytoplasmic domain using the standard protocols. Human cell lines HEK293, Jurkat and HT-29 were cultured in appropriate media (Dulbecco's modification of Eagle's medium, RPMI 1640) supplemented with fetal calf serum (10%) and standard antibiotics.
Induction of apoptosis
Apoptosis was induced by antibody-mediated crosslinking of CEACAM1 as described previously (Nittka et al., 2004) or incubation with human CEA (4-100 ng per well). Apoptosisdependent CEACAM1 processing was assessed in aliquots of 2 Â 10 6 cells which were incubated (16-24 h) with camptothecin (0.5 mM), etoposide (50 mM), cycloheximide (50-100 mM), actinomycin D (0.5-1 mM) and Fas-ligand (0.2 mg ml À1 ), respectively.
Western blot
Normal and deglycosylated cell extracts were separated by SDS-PAGE and transferred onto 0.2 mM nitrocellulose membranes overnight (4 1C). After antibody incubation, signals were visualized by ECL (Bio-Rad, Mu¨nchen, Germany). N-linked sugar side chains were removed using 500 U PNGase F (NEB, Frankfurt, Germany).
Caspase inhibition and assessment of caspase activity To inhibit caspases, cells were preincubated with the pancaspase inhibitor Z-VAD.fmk (200 mM) and Ac-YVAD.fmk (400 mM) 1 h before apoptosis induction. The latter selectively blocks caspase-1, -2 and -4, respectively. Z-FA.fmk (200 mM) served as negative control. Apoptosis was assessed using the Cell Death Detection ELISA Plus kit (Roche Diagnostics, Activation and processing of CEACAM1 during apoptosis S Nittka et al Mannheim, Germany). To detect active caspases, aliquots of 5 Â 10 6 cells were lysed in caspase lysis buffer (10 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.01% Triton X-100, pH 7.4) and protein concentrations were determined. For each assay, 100-200 mg total protein was incubated with assay buffer (20 mM PIPES, 4 mM EDTA, 0.2% CHAPS, pH 7.4) and 5 ml pNAlabelled caspase substrate. The following substrates (specifities indicated) were used: Ac-VEID-pNA (caspase-6), Ac-IETDpNA (caspase-8), Ac-LEVD-pNA (caspase-4), Ac-WEHDpNA (caspase-1, -4, -5) and Ac-DEVD-pNA (caspase-3, -6, -7, -8, -10). Substrate cleavage was measured using a Victor 3 ELISA plate reader (PerkinElmer, Dreieich, Germany).
Flow cytometry and immunofluorescence
Assessment of CEACAM1 cell surface expression was performed by flow cytometry (FACSCalibur, Becton Dickinson, Heidelberg, Germany). Apoptotic cells and controls were stained using specific antibodies against the CEACAM1 (T84.1, 0.1 mg ml À1 ), CEA (T84.66, 1 mg ml À1 ) and CEACAM6 (By114, 1:100), respectively, and a goat PE-conjugated antiserum (DAKO). C-terminal CEACAM1 cleavage was visualized using the antibody mAb 7-2.3 (20 mg ml
À1
) and apoptotic nuclei were stained with Hoechst dye.
Protease assays
Non-caspase protease activity was assessed in total protein extracts after incubation with resorufin-labelled casein, a class independent protease substrate. After the addition of various protease inhibitors, substrates were added and protease activities were determined on a Victor3 plate reader (PerkinElmer) using the fluorescence signal generated by resorufin-casein cleavage. The protease inhibitors used were antipain (74 mM), bestatin (130 mM), chymostatin (100 mM), E-64 (28 mM), leupeptin (10 mM), pepstatin (1 mM), phosphoramidon (0.6 mM) and pefabloc SC (4 mM), respectively.
